Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL

18 Jan 2023

Abstract excerpt

The acquisition of genetic abnormalities engendering oncogene dysregulation underpins cancer development. Certain proto-oncogenes possess several dysregulation mechanisms, yet how each mechanism impacts clinical outcome is unclear. Using T-cell acute lymphoblastic leukemia (T-ALL) as an example, we show that patients harboring 5'super-enhancer (5'SE) mutations of the TAL1 oncogene identifies a specific patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Chronic Myeloid Leukemia Treatments
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36650499
DOI: 10.1186/s12943-022-01701-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALLPMID 36650499Read ↗

TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.Semantic proximity Read ↗

Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.Semantic proximity Read ↗

Reactivation of a TAL1 progenitor cell enhancer region by non-coding somatic variants in T-lineage acute lymphoblastic leukemiaSemantic proximity Read ↗

The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia.Semantic proximity Read ↗

MYC in T-cell acute lymphoblastic leukemia: functional implications and targeted strategiesSemantic proximity Read ↗

Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemiaSemantic proximity Read ↗

Harnessing ALDH1A2 vulnerability in T-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Friend or foe: can activating mutations in NOTCH1 contribute to a favorable treatment outcome in patients with T-ALL?Semantic proximity Read ↗

ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signallingSemantic proximity Read ↗

Super Enhancer Regulatory Gene FYB1 Promotes the Progression of T Cell Acute Lymphoblastic Leukemia by Activating IGLL1Semantic proximity Read ↗

LZTR1 functions as a two-hit tumor suppressor in childhood acute lymphoblastic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.